ライフサイエンスコーパス: organ transplant

1 ystemic autoimmune diseases, and 2 following organ transplants).

2 0.3%), liver transplant; and 6 (1.8%), mixed-organ transplant.

3 e saved to date during the 25 years of solid-organ transplant.

4 nts benefit from avoidance of morbidities of organ transplant.

5 y with 1 or more clinical risk factors or an organ transplant.

6 ong patients receiving hematopoietic cell or organ transplant.

7 cytomegalovirus (CMV) infections after solid organ transplant.

8 myocardial infarction, vascular surgery, and organ transplant.

9 lly related to immunomodulation during solid-organ transplant.

10 rimary cutaneous T-cell lymphoma after solid organ transplant.

11 ort- and long-term clinical outcome of solid organ transplant.

12 and show great promise for women with solid-organ transplant.

13 ied to achieve these goals in the context of organ transplant.

14 d risk is higher among those who received an organ transplant.

15 re >/=2 years old and have not had HIV or an organ transplant.

16 d risk is higher among those who received an organ transplant.

17 transplant and patients who had received an organ transplant.

18 rials, such as foods, waterborne paints, and organ transplants.

19 il CMV infection and to purge the virus from organ transplants.

20 ical failure and rejection compared to other organ transplants.

21 nic hepatitis E who were recipients of solid-organ transplants.

22 ure, wound healing, and chronic rejection of organ transplants.

23 jor obstacle for long-term survival of solid organ transplants.

24 (Abs) in highly sensitized patients awaiting organ transplants.

25 ections occurred more frequently among solid organ transplant (31%) and dialysis (17%) patients.

26 Organs from donors with ITP resulted in 49 organ transplants (31 kidney, 14 liver, four heart), wit

27 ords of 59 patients who had received a solid-organ transplant (37 kidney-transplant recipients, 10 li

28 t and increase the probability of successful organ transplant, a clinical method defined as donor-spe

29 Created by the US National Organ Transplant Act in 1984, the Scientific Registry of

30 in immunocompromised individuals, including organ transplant and AIDS patients.

31 Thirty-five patients with a solid-organ transplant and chronic hepatitis E virus infection

32 rately for individuals who never received an organ transplant and patients who had received an organ

33 s in the United Kingdom between the need for organ transplant and supply of deceased donor organs.

34 ce of EBV+ PTLD is variable depending on the organ transplanted and whether the recipient has preexis

35 small intestine by cell-turnover analysis in organ transplants and by retrospective cell birth dating

36 cells; it also underlies T cell rejection of organ transplants and drives graft-versus-host disease.

37 r ESBL-producing Enterobacteriaceae in solid organ transplants and MCS device recipients are essentia

38 stinct populations, those patients receiving organ transplants and those waiting to receive a transpl

39 and numerous other solid organ malignancies, organ transplant, and immune suppression for nonmalignan

40 by donor/recipient CMV serostatus, year and organ transplanted, and clinical manifestation.

41 trials to treat patients with cancer, solid organ transplants, and autoimmune diseases.

42 splantation is among the lowest of all solid-organ transplants, and current diagnostic tests often fa

43 uce rejection compared with most other solid organ transplants, and simultaneous transplantation of l

44 f reproductive age who have received a solid-organ transplant are at risk for unplanned pregnancy.

45 Outcomes after solid organ transplants are improving; for adult patients graf

46 Organ transplants are rapidly rejected because T cells i

47 he goals of tolerance in patients with solid organ transplants are to eliminate the lifelong need for

48 ean [SEM] expression, 3.58 [1.50]; P = .15), organ transplant-associated cSCC (mean [SEM] expression,

49 tients with end-stage renal disease or solid organ transplants because very few are uninsured.

50 capable of triggering graft rejection of an organ transplanted between identical twins remains unkno

51 mune responses and destruction of allogeneic organ transplants, but how this process is regulated on

52 of Transplant Recipients report cards of US organ transplant center performance are publicly availab

53 performed a cross-country survey of Canadian Organ Transplant centers to determine organ utilization

54 Six organ transplanted children with GPTD were included in t

55 s I removing activity under recognized whole organ transplant conditions of lowered temperature.

56 ti-HBc positivity in the absence of HBsAg in organ transplant donors and in candidate patients for ch

57 etrospective analysis of UNOS data for solid-organ transplant during a 25-year period (September 1, 1

58 llion life-years were saved to date by solid-organ transplants during a 25-year study period.

59 ues to remain much higher than the number of organs transplanted each year.

60 rejection is the most common cause of solid organ transplant failure.

61 An increasing number of older people receive organ transplants for various end-stage conditions.

62 The charts of all patients receiving a solid organ transplant from 1990-2008 evaluated in the dermato

63 with end organ failure can safely receive an organ transplant from an HIV uninfected donor.

64 ht to determine the number and proportion of organs transplanted from donors who received cardiopulmo

65 each treatment group and the total number of organs transplanted from each donor.

66 ne oxygenation and to analyze the outcome of organs transplanted from these donors.

67 In vascularized organ transplants, gender mismatches have higher rates o

68 Unwanted T cell responses during organ transplant, graft-versus-host disease, and allergi

69 Successful engraftment of organ transplants has traditionally relied on preventing

70 ation and avoidance protocols for post-solid organ transplant have been developed.

71 Immunosuppressed patients with solid organ transplants have an increased risk for nonmelanoma

72 ers, bridges research in the fields of solid organ transplant, hematopoietic cell transplant, and org

73 ailure or rejection (HR 3.2), previous solid organ transplant (HR 1.7), and several comorbidities.

74 ) in a cohort of US OTRs receiving a primary organ transplant in 2003 or 2008.

75 wever, most patients on the waiting list for organ transplant in the United States are nonwhite.

76 ibiting substantial growth in deceased donor organ transplants in Iran.

77 ondary outcomes were the rates of individual organs transplanted in each treatment group and the tota

78 ed after placement of different vascularized organ transplants, including hearts and kidneys, whereas

79 A computer-learning software package (the Organ Transplant Information System) was made available

80 In transplantation, the survival of organs transplanted into obese patients is reduced compa

81 disease consultation in recipients of solid organ transplant is associated with increased LOS and ho

82 variable direct costs and time allocated per organ transplanted is significantly higher in donors tha

83 Transcriptional profiling of organ transplants is increasingly defining the biologica

84 For HIV-positive individuals needing an organ transplant, issues of access, risk, and consent mu

85 event graft rejection in patients undergoing organ transplant it was also used to treat several syste

86 5 years or older with NSCLC who had received organ transplants (kidney, liver, heart, or lung) before

87 nts with cystic fibrosis who had received an organ transplant, optimal colonoscopy screening should s

88 uring therapeutic interventions such as cell/organ transplant or gene/protein replacement therapy.

89 ory of human immunodeficiency virus, cancer, organ transplants, or hereditary disease (albinism and x

90 Receiving a solid organ transplant owing to late-stage organ failure, foll

91 Nocardia thailandica in a 66-year-old solid organ transplant patient from Connecticut, which was ide

92 Organ transplant patients are administered the calcineur

93 markers aimed at identifying long-term solid-organ transplant patients at high risk of developing can

94 uggest that chronic administration of CsA to organ transplant patients could have significant effects

95 One hundred and fifty-three solid organ transplant patients were enrolled, including lung

96 tudied six cases of CMV replication in solid organ transplant patients whose genotypic testing showed

97 Solid organ transplant patients with first episode of CMV dise

98 used to treat chronic HEV infection in solid-organ transplant patients with some success.

99 apenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal data on

100 In solid organ transplant patients, global suppression of innate

101 chronic hepatitis E virus infection in solid-organ transplant patients.

102 and safety of vismodegib in immunosuppressed organ transplant patients.

103 medication, could predict adherence in solid organ transplant patients.

104 n ORF1 and the outcome of infection in solid-organ transplant patients.

105 d as a cause of persistent diarrhea in solid organ transplant patients.

106 d individuals, such as bone marrow and solid organ transplant patients.

107 cryptosporidiosis cases identified in solid organ transplanted patients between 2006 and 2010 in Fra

108 asting clinical disorder that may develop in organ-transplanted pediatric recipients.

109 The primary outcome measure was 3 or more organs transplanted per donor and binary logistic regres

110 ocured per donor was 2.59, and the number of organs transplanted per donor was 1.68.

111 Independent predictors of 3 or more organs transplanted per donor were older age (odds ratio

112 ed with the standard risk donors (3.9 vs 4.2 organs transplanted per donor).

113 ECDs is associated with achieving 3 or more organs transplanted per donor.

114 Forty-three percent had 3 or more organs transplanted per donor.

115 71 ECDs with a mean (SD) number of 2.1 (1.3) organs transplanted per donor.

116 e actual donors; range: 20.0-57.0%); and (2) organs transplanted per possible donor (range: 0.52-1.74

117 With a growing immunosuppressed organ transplant population at high risk for basal cell

118 neous SCC either developed in UVR-exposed or organ transplant population.

119 on complicated by meningoencephalitis in our organ transplant population.

120 subsequent malignancy, however, the risk in organ transplant populations has not been evaluated.

121 cancer of any type to determine the type of organ transplanted, pretransplant and posttransplant can

122 splantation lags behind that for other solid organ transplants, primarily because of allograft reject

123 (IRI) is an inevitable event in conventional organ transplant procedure and is associated with signif

124 with providing program-specific reports for organ transplant programs in the United States.

125 ases of PTLD were identified with 1392 solid-organ transplant recipient controls.

126 he intent of the PHS guideline is to improve organ transplant recipient outcomes by reducing the risk

127 atients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis durin

128 ears were saved (observed to date) per solid-organ transplant recipient.

129 e medical record review of patients who were organ transplant recipients (154 were white and 259 nonw

130 We reported 47 solid organ transplant recipients (41 kidneys) with cryptospor

131 gate drug-virome interactions in a cohort of organ transplant recipients (656 samples, 96 patients) a

132 Liver versus other types of organ transplant recipients (adjusted odds ratio [OR], 6

133 Of 495 high-risk organ transplant recipients (average age = 54 years, tim

134 Overall, 10649 organ transplant recipients (mean [SD] age, 51 [12] year

135 d arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8% in ste

136 onazole in the development of skin cancer in organ transplant recipients (OTRs) and offers suggestion

137 Solid-organ transplant recipients (OTRs) are at an increased r

138 Organ transplant recipients (OTRs) have a 100-fold incre

139 ll carcinoma (SCC) and other skin cancers in organ transplant recipients (OTRs), but evidence from mu

140 ed an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has estimat

141 cancer has been well characterized in white organ transplant recipients (OTRs); however, most patien

142 De novo solid organ transplant recipients (SOTR) have a steep learning

143 Solid organ transplant recipients (SOTR) with a pretransplant

144 accine effectiveness is not optimal in solid organ transplant recipients (SOTR).

145 Immunosuppression (IS), such as in solid-organ transplant recipients (SOTRs) and patients with hu

146 Solid-organ transplant recipients (SOTRs) are at greater risk

147 h CMV DNA-positive plasma samples from solid-organ transplant recipients (SOTRs) were tested.

148 tributor to morbidity and mortality in solid organ transplant recipients (SOTRs).

149 iple risk factors for CNS processes in solid organ transplant recipients and establishes a timeline t

150 ecipients led to its subsequent use in other organ transplant recipients and for treatment of a varie

151 se in immunocompromised individuals, such as organ transplant recipients and infants infected in uter

152 disorder (PTLD) is a serious complication in organ transplant recipients and is most often associated

153 Diabetes is prevalent among solid organ transplant recipients and is universal among islet

154 risk are similar to those observed in solid organ transplant recipients and patients with autoimmune

155 advanced stage, which suggests that nonwhite organ transplant recipients are at even higher risk.

156 Solid organ transplant recipients are at increased risk for de

157 Solid-organ transplant recipients are at increased risk of dev

158 Conclusions and Relevance: Nonwhite organ transplant recipients are at risk for developing s

159 atment of chronic hepatitis C virus in solid organ transplant recipients are limited.

160 Organ transplant recipients are treated with posttranspl

161 A total of 840 solid-organ transplant recipients at risk for CMV infection we

162 In conclusion, high-risk organ transplant recipients carry a substantial measurab

163 tion, a significant number of nonrenal solid organ transplant recipients develop chronic kidney disea

164 Another cluster of solid organ transplant recipients developed encephalitis from

165 Risk factors for nonwhite organ transplant recipients differ between races/ethnici

166 Organ transplant recipients face life-long immunosuppres

167 ted cluster of febrile illness among 3 solid organ transplant recipients from a common donor.

168 Treatment-related immunosuppression in organ transplant recipients has been linked to increased

169 Solid organ transplant recipients have a high incidence of cen

170 Importance: Organ transplant recipients have a higher incidence of s

171 Solid organ transplant recipients have heightened risk for dif

172 Solid organ transplant recipients have increased risk for deve

173 d a Swedish population-based cohort of solid organ transplant recipients in the National Patient Regi

174 nts, which contains information on all solid organ transplant recipients in the United States, were l

175 The increased skin cancer incidence in organ transplant recipients is well-known, but the skin

176 induction protocols a 'standard of care' for organ transplant recipients over the next decade?" In a

177 ocyte function-associated antigen (LFA)-1 in organ transplant recipients prolongs allograft survival.

178 t outcomes during CMV infection in 291 solid organ transplant recipients receiving valganciclovir or

179 Still, the risk of SCC in organ transplant recipients remains much higher than in

180 and sun exposure/emigration history in Asian organ transplant recipients should be documented.

181 ic pathogens in HIV-infected populations and organ transplant recipients that are often associated wi

182 ers et al. (2015) demonstrate in a cohort of organ transplant recipients that betapapillomavirus sero

183 erobacteriaceae and CRE carriage among solid organ transplant recipients to inform management of this

184 on SCCs on sun-exposed areas of the skin in organ transplant recipients treated by calcineurin inhib

185 Organ transplant recipients underwent full skin examinat

186 r was assessed among 118,440 Caucasian solid organ transplant recipients using multivariate Cox regre

187 Organ transplant recipients were excluded.

188 Solid organ transplant recipients were identified within the N

189 as used to evaluate lung cancer prognosis in organ transplant recipients while adjusting for confound

190 Non-lung solid organ transplant recipients who developed NSCLC had wors

191 In solid organ transplant recipients who presented at our institu

192 We conclude that organ transplant recipients with cancer history are at a

193 Organ transplant recipients with CF should initiate CRC

194 hat elevated osteoprotegerin levels in solid organ transplant recipients with CMV infection may refle

195 We describe four solid-organ transplant recipients with donor-derived West Nile

196 The proportion of examined organ transplant recipients with histopathologically con

197 ffects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV viremia.

198 Organ transplant recipients with the highest skin cancer

199 The study cohort included 8026 organ transplant recipients, 5224 men (65.1%), with a me

200 lem in immunocompromised individuals such as organ transplant recipients, although the mechanism rema

201 he current status of CMV resistance in solid organ transplant recipients, and provide diagnostic and

202 tory of HPV infection, particularly in black organ transplant recipients, and sun exposure/emigration

203 In this study of 649 solid organ transplant recipients, followed prospectively for

204 d be part of posttransplantation care in all organ transplant recipients, including nonwhite patients

205 l vasculature that occurs in 0.5-5% of solid organ transplant recipients, most commonly associated wi

206 e susceptibility to CMV replication in solid-organ transplant recipients, particularly in patients no

207 diarrhea is a frequent complaint among solid organ transplant recipients, the contribution of infecti

208 noma skin cancer is well recognized in solid-organ transplant recipients, the risk of skin cancer in

209 or invasive mold infections among 1101 solid organ transplant recipients, thereby strengthening their

210 Solid organ transplant recipients, who are medically immunosup

211 se II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20(+) PTLD unrespons

212 rcinoma (NPC), and lymphomas that develop in organ transplant recipients.

213 e groin and genitalia is imperative in black organ transplant recipients.

214 r for cytomegalovirus (CMV) disease in solid organ transplant recipients.

215 r cause of graft loss and mortality in solid organ transplant recipients.

216 ne the underlying mechanism of recurrence in organ transplant recipients.

217 ce in the prevention of skin cancer in black organ transplant recipients.

218 mentation, which was not seen in other solid-organ transplant recipients.

219 immunocompromised patients and particularly organ transplant recipients.

220 al in immuno-compromised individuals such as organ transplant recipients.

221 frequently causes noninfectious diarrhea in organ transplant recipients.

222 e incidence of rejection in HIV-to-HIV solid organ transplant recipients.

223 ver an 18-month period of hospitalized solid organ transplant recipients.

224 of cytomegalovirus (CMV) infection in solid-organ transplant recipients.

225 receiving immunosuppressing drugs, and solid organ transplant recipients.

226 harges among lung transplant and other solid-organ transplant recipients.

227 tious disease-related complications in solid organ transplant recipients.

228 ases of antibody-mediated rejection in solid organ transplant recipients.

229 or chronic hepatitis in some pediatric solid organ transplant recipients.

230 ons are likely to be relevant to other solid organ transplant recipients.

231 fects posttransplantation mortality in solid organ transplant recipients.

232 ese viruses are reported only in 1% of solid organ transplant recipients.

233 non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients.

234 potentially life-threatening complication in organ transplant recipients.

235 arly- and late-onset PTLD in pediatric solid organ transplant recipients.

236 wth and safety parameters in pediatric solid organ transplant recipients.

237 compromised individuals, especially in solid-organ transplant recipients.

238 d adjunct immunosuppressive therapy in solid organ transplant recipients.

239 ost common single cause of death observed in organ transplant recipients.

240 cognized but uncommon complications in solid organ transplant recipients.

241 nues to affect a high proportion of thoracic organ transplant recipients.

242 and the incidence of skin cancer in nonwhite organ transplant recipients.

243 eading cause of cancer mortality among solid organ transplant recipients.

244 MF-59) may lead to greater immunogenicity in organ transplant recipients.

245 413 patients (62.7%) evaluated were nonwhite organ transplant recipients; 264 were men, and 149 were

246 V infection, 18 HEV-exposed immunosuppressed organ-transplant recipients (8 with chronic HEV), and 27

247 se of skin cancer after retransplantation in organ-transplant recipients who have already developed p

248 Twenty-four solid-organ-transplant recipients with chronic hepatitis E vir

249 Organ-transplant-recipients exhibit cancerization of the

250 Through linkage of the US solid organ transplant registry with 15 state/regional cancer

251 ants, may actually be potent facilitators of organ transplant rejection in the absence of T-bet and R

252 to discuss the current and historical solid organ transplant-related disruptions in the supply of me

253 r HLA class I has potential use in the whole organ transplant setting with retained activity at lower

254 Records of solid organ transplant (SOT) and hematopoietic cell transplant

255 nt of latent tuberculosis infection in solid-organ transplant (SOT) candidates.

256 d molecular pretransplant screening in solid organ transplant (SOT) donors and recipients in north ce

257 Two groups were identified: the solid organ transplant (SOT) group (n = 15; 12 ITX and 3 modif

258 tentially fatal disorder arising after solid organ transplant (SOT) or hematopoietic stem cell transp

259 r-stick DBS and plasma samples from 35 solid-organ transplant (SOT) patients.

260 In the solid organ transplant (SOT) population, manifestations of VZV

261 Solid organ transplant (SOT) recipients are at elevated risk o

262 Solid organ transplant (SOT) recipients are at risk of nocardi

263 itution inflammatory syndrome (IRS) in solid-organ transplant (SOT) recipients are not known.

264 Approximately 3%-10% of solid organ transplant (SOT) recipients in CRE-endemic areas d

265 acteremia caused by these organisms in solid-organ transplant (SOT) recipients is lacking.

266 mmune reconstitution syndrome (IRS) in solid organ transplant (SOT) recipients with cryptococcosis ha

267 ve the potential to affect outcomes in solid organ transplant (SOT) recipients.

268 among hematopoietic stem cell but not solid-organ transplant (SOT) recipients.

269 istant (XDR) Pseudomonas aeruginosa in solid organ transplant (SOT) recipients.

270 s an emerging and important problem in solid organ transplant (SOT) recipients.

271 s associated with histoplasmosis after solid organ transplant (SOT), we report a large series of hist

272 multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous s

273 ecting 0.04% to 3.5% of patients after solid organ transplant (SOT).

274 Sepsis is a serious complication of solid organ transplant (SOT).

275 sis infection (LTBI) is recommended in solid organ transplant (SOT).

276 fter hematopoietic stem cell (HSCT) or solid organ transplant (SOT).

277 over the years shows that, similar to solid organ transplants (SOT), human VCA can also develop CR.

278 Co-management with a solid organ transplant specialist is helpful for the monitorin

279 ng revised CMV guidelines should incorporate organ transplant-specific thresholds of prior drug expos

280 d outcomes across a range of different solid-organ transplant studies.

281 n, which is in sharp contrast to other solid organ transplants, such as kidney, lung, and heart trans

282 ed by ischemic pulmonary conditions prior to organ transplant that often lead to complications.

283 The molecular entities present on a cell or organ transplant that trigger the innate immune response

284 ients already on immunosuppression for other organ transplant, there is little additional risk involv

285 s with cystic fibrosis who never received an organ transplant; this strategy prevented 79% of deaths

286 s with cystic fibrosis who never received an organ transplant; this strategy prevented 79% of deaths

287 e, type and location of skin cancer, type of organ transplanted, time to diagnosis of skin cancer aft

288 During 2009 and 2010, 2 clusters of organ transplant-transmitted Balamuthia mandrillaris, a

289 the context of various clinical settings and organ transplant types (kidney, heart, lung, liver, panc

290 reexisting autoreactive T cells affect solid-organ transplants under these conditions is unknown.

291 procurement were measured and amortized per organ transplanted using permutation methods and statist

292 ls with inflammatory bowel diseases or solid-organ transplants, virome dynamics in allogeneic hematop

293 lyses showed that having received a non-lung organ transplant was associated with poorer OS (P < 0.05

294 In contrast, the amortized time per organ transplanted was significantly longer in the NED d

295 ants and reduced long-term survival of solid organ transplants, we hypothesized that conventional imm

296 ed from aerosolized viral exposure or tissue/organ transplant were excluded (n = 20).

297 ast, the amortized variable direct costs per organ transplanted were significantly higher in the NED

298 Preemptive and multiple-organ transplants were excluded.

299 ovariates RESULTS: A total of 1900 abdominal organ transplants were performed during the study period

300 d Transplantation Network data, 28 051 solid organ transplants were performed in 2012.